JP2016520319A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520319A5
JP2016520319A5 JP2016516171A JP2016516171A JP2016520319A5 JP 2016520319 A5 JP2016520319 A5 JP 2016520319A5 JP 2016516171 A JP2016516171 A JP 2016516171A JP 2016516171 A JP2016516171 A JP 2016516171A JP 2016520319 A5 JP2016520319 A5 JP 2016520319A5
Authority
JP
Japan
Prior art keywords
seq
activity
variant
cell
onui
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016516171A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520319A (ja
JP6488283B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/061186 external-priority patent/WO2014191525A1/en
Publication of JP2016520319A publication Critical patent/JP2016520319A/ja
Publication of JP2016520319A5 publication Critical patent/JP2016520319A5/ja
Application granted granted Critical
Publication of JP6488283B2 publication Critical patent/JP6488283B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016516171A 2013-05-31 2014-05-28 C−cケモカイン受容体5型(ccr5)遺伝子を開裂するlaglidadgホーミングエンドヌクレアーゼおよびその用途 Active JP6488283B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201370302 2013-05-31
DKPA201370302 2013-05-31
PCT/EP2014/061186 WO2014191525A1 (en) 2013-05-31 2014-05-28 A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof

Publications (3)

Publication Number Publication Date
JP2016520319A JP2016520319A (ja) 2016-07-14
JP2016520319A5 true JP2016520319A5 (enExample) 2017-07-06
JP6488283B2 JP6488283B2 (ja) 2019-03-20

Family

ID=48628225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016516171A Active JP6488283B2 (ja) 2013-05-31 2014-05-28 C−cケモカイン受容体5型(ccr5)遺伝子を開裂するlaglidadgホーミングエンドヌクレアーゼおよびその用途

Country Status (6)

Country Link
US (1) US10006052B2 (enExample)
EP (1) EP3004149B1 (enExample)
JP (1) JP6488283B2 (enExample)
AU (1) AU2014273089B2 (enExample)
CA (1) CA2913871C (enExample)
WO (1) WO2014191525A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
JP2016536021A (ja) 2013-11-07 2016-11-24 エディタス・メディシン,インコーポレイテッド CRISPR関連方法および支配gRNAのある組成物
US20150165054A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting caspase-9 point mutations
US9725710B2 (en) 2014-01-08 2017-08-08 Flodesign Sonics, Inc. Acoustophoresis device with dual acoustophoretic chamber
CA2956224A1 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
WO2017053729A1 (en) 2015-09-25 2017-03-30 The Board Of Trustees Of The Leland Stanford Junior University Nuclease-mediated genome editing of primary cells and enrichment thereof
DK3359660T3 (en) 2015-10-05 2020-02-17 Prec Biosciences Inc Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
DK3359184T3 (da) 2015-10-05 2020-06-15 Prec Biosciences Inc Genetisk modificerede celler, der omfatter et modificeret gen fra konstant alfaregion i human t-cellereceptor
EP4434589A3 (en) 2015-10-23 2025-05-14 President and Fellows of Harvard College Evolved cas9 proteins for gene editing
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
WO2018022619A1 (en) * 2016-07-25 2018-02-01 Bluebird Bio, Inc. Bcl11a homing endonuclease variants, compositions, and methods of use
JP7231935B2 (ja) 2016-08-03 2023-03-08 プレジデント アンド フェローズ オブ ハーバード カレッジ アデノシン核酸塩基編集因子およびそれらの使用
US11661590B2 (en) 2016-08-09 2023-05-30 President And Fellows Of Harvard College Programmable CAS9-recombinase fusion proteins and uses thereof
EP3500696A4 (en) * 2016-08-16 2020-04-08 Bluebird Bio, Inc. VARIANTS OF IL-10 ALPHA RECEPTOR HOMING ENDONUCLEASE, COMPOSITIONS AND METHODS OF USE
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
ES2952525T3 (es) 2016-09-08 2023-11-02 2Seventy Bio Inc Variantes de endonucleasa homing PD-1, composiciones y métodos de uso
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
EP3526334A4 (en) * 2016-10-17 2020-09-30 Bluebird Bio, Inc. TGFBETA R2 ENDONUCLEASE VARIANTS, COMPOSITIONS AND METHODS OF USE
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
WO2018176009A1 (en) 2017-03-23 2018-09-27 President And Fellows Of Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11767512B2 (en) 2017-04-13 2023-09-26 Cellectis Sequence specific reagents targeting CCR5 in primary hematopoietic cells
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
KR102742817B1 (ko) 2017-05-25 2024-12-17 리제너론 파마슈티칼스 인코포레이티드 Cblb 엔도뉴클레아제 변이체, 조성물 및 사용 방법
CA3068465A1 (en) 2017-06-30 2019-01-03 Precision Biosciences, Inc. Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
WO2019139645A2 (en) 2017-08-30 2019-07-18 President And Fellows Of Harvard College High efficiency base editors comprising gam
KR20200121782A (ko) 2017-10-16 2020-10-26 더 브로드 인스티튜트, 인코퍼레이티드 아데노신 염기 편집제의 용도
JP2021507561A (ja) 2017-12-14 2021-02-22 フロデザイン ソニックス, インク.Flodesign Sonics, Inc. 音響トランスデューサドライバ及びコントローラ
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US20210002621A1 (en) * 2017-12-20 2021-01-07 Bluebird Bio, Inc. Ctla4 homing endonuclease variants, compositions, and methods of use
US11786554B2 (en) 2018-04-12 2023-10-17 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
EP3781677A4 (en) 2018-04-16 2022-01-19 University of Massachusetts COMPOSITIONS AND METHODS FOR IMPROVED GENE EDITTING
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
US12060419B2 (en) 2018-06-14 2024-08-13 Regeneron Pharmaceuticals, Inc. CD79A chimeric antigen receptors
US12522807B2 (en) 2018-07-09 2026-01-13 The Broad Institute, Inc. RNA programmable epigenetic RNA modifiers and uses thereof
WO2020072059A1 (en) 2018-10-04 2020-04-09 Bluebird Bio, Inc. Cblb endonuclease variants, compositions, and methods of use
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
AU2019395334A1 (en) 2018-12-10 2021-06-24 Regeneron Pharmaceuticals, Inc. PDCD-1 homing endonuclease variants
US12404500B2 (en) 2018-12-10 2025-09-02 Novo Nordisk A/S Homing endonuclease variants
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
MX2021011426A (es) 2019-03-19 2022-03-11 Broad Inst Inc Metodos y composiciones para editar secuencias de nucleótidos.
WO2020214842A1 (en) 2019-04-17 2020-10-22 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
EP3987024A4 (en) 2019-06-20 2023-11-01 University Of Massachusetts COMPOSITIONS AND METHODS FOR ENHANCED GENOMIC EDITING
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
US20230167431A1 (en) * 2020-04-28 2023-06-01 City Of Hope Tagged gene editing technology for clinical cell sorting and enrichment
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
JP2023531537A (ja) 2020-06-30 2023-07-24 メンドゥス・ベスローテン・フェンノートシャップ 卵巣癌ワクチンでの白血病由来細胞の使用
CA3212351A1 (en) 2021-03-12 2022-09-15 Mendus B.V. Methods of vaccination and use of cd47 blockade
CA3237482A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
GB202117314D0 (en) 2021-11-30 2022-01-12 Clarke David John Cyclic nucleic acid fragmentation
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011156430A2 (en) * 2010-06-07 2011-12-15 Fred Hutchinson Cancer Research Center Generation and expression of engineered i-onui endonuclease and its homologues and uses thereof
EP2680877B1 (en) * 2011-02-28 2019-07-10 Seattle Children's Research Institute Coupling endonucleases with end-processing enzymes drive high efficiency gene disruption
CA3111953C (en) * 2011-04-05 2023-10-24 Cellectis Method for the generation of compact tale-nucleases and uses thereof
WO2013009525A1 (en) * 2011-07-08 2013-01-17 Cellectis S.A. Method for increasing the efficiency of double-strand break-induced mutagenssis
US20130210151A1 (en) * 2011-11-07 2013-08-15 University Of Western Ontario Endonuclease for genome editing

Similar Documents

Publication Publication Date Title
JP2016520319A5 (enExample)
JP2016520320A5 (enExample)
US11497773B2 (en) Genetically engineered t cells with regnase-1 and/or TGFBRII disruption have improved functionality and persistence
US20240175046A1 (en) Vectors
AU2022215269A1 (en) Genetically engineered cells and methods of making the same
TW202028466A (zh) 編輯RNAs的方法以及組成物
JP2021521855A (ja) ヘモグロビン関連変異の編集のための相同組換え修復用鋳型の設計およびその送達
JP2017532955A5 (enExample)
JP2017501688A (ja) 変異cas9タンパク質
JP2015533786A5 (enExample)
JP2017018125A5 (enExample)
US20250250350A1 (en) Immune cells having co-expressed shrnas and logic gate systems
HRP20211468T1 (hr) Postupci i pripravci za nukleazno posredovani inženjering genoma i ispravak u krvotvornim matičnim stanicama
WO2013186563A3 (en) Factor viii sequences
AU2021369494A1 (en) Safe harbor loci
KR20250068649A (ko) 공동 발현된 tgfbr shrna를 갖는 면역 세포
EP3841114A1 (en) Methods and compositions for rna expression of myc inhibitors
US20250222103A1 (en) Immune cells with combination gene perturbations
JP2015174843A5 (enExample)
US20250188432A1 (en) Reversal of exhaustion of hiv-1 specific ctls by crispr-mediated disruption of pd-1 gene
HK40120803A (zh) 靶向psma和ca9的工程化受体的系统
CN118843692A (zh) 具有共表达的shRNA和逻辑门系统的免疫细胞
CN114807155A (zh) 用于基因编辑的组合物及其应用
CN112608945A (zh) 一种改造的ppp1r12a环状rna载体及其应用
NZ742751A (en) Materials and methods for treatment of titin-based myopathies and other titinopathies